News | February 13, 2026
Lupin Q3 FY26 consolidated PAT jumped 37.4% to Rs. 1,180.5 Cr
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Subscribe To Our Newsletter & Stay Updated
